Abstract
Photodynamic therapy (PDT) combines photosensitizer, visible light and oxygen, which has the characteristics of high selectivity, minimal invasiveness, low side effect, and allowing repetitive application. The photophysics and mechanisms leading to cell death mediated by PDT have been studied extensively, and PDT has been approved as the modality for superficial tumors and non-cancerous diseases worldwide. For non-dermatogoical applications, the photosensitizers are delivered systemically. Selective therapeutic effect against tumor tissues can be provided by the nature of drugs and tumor physiology. Improved targeting photosensitizer helps preventing damage to the surrounding healthy tissue and lowering dose of drugs and light. The use of nanotechnology in photosensitizer delivery is an attractive approach because nanomaterials may satisfy the need for enhancing PDT efficacy. Recent advances in the use of nanotechnology for PDT application include formulation of biodegradable and non-degradable nanoparticles as passive carriers for photosensitizing agents as well as synthesizing photosensitizer-specific target moiety conjugates for active targeting. This article focuses on passive and active targeting strategies involving nanotechnology to enhance PDT efficacy for cancers.
Keywords: Photodynamic therapy, nanoparticle, photosensitizer, targeted delivery, anticancer treatment
Current Drug Metabolism
Title: Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Volume: 10 Issue: 8
Author(s): Wen-Tyng Li
Affiliation:
Keywords: Photodynamic therapy, nanoparticle, photosensitizer, targeted delivery, anticancer treatment
Abstract: Photodynamic therapy (PDT) combines photosensitizer, visible light and oxygen, which has the characteristics of high selectivity, minimal invasiveness, low side effect, and allowing repetitive application. The photophysics and mechanisms leading to cell death mediated by PDT have been studied extensively, and PDT has been approved as the modality for superficial tumors and non-cancerous diseases worldwide. For non-dermatogoical applications, the photosensitizers are delivered systemically. Selective therapeutic effect against tumor tissues can be provided by the nature of drugs and tumor physiology. Improved targeting photosensitizer helps preventing damage to the surrounding healthy tissue and lowering dose of drugs and light. The use of nanotechnology in photosensitizer delivery is an attractive approach because nanomaterials may satisfy the need for enhancing PDT efficacy. Recent advances in the use of nanotechnology for PDT application include formulation of biodegradable and non-degradable nanoparticles as passive carriers for photosensitizing agents as well as synthesizing photosensitizer-specific target moiety conjugates for active targeting. This article focuses on passive and active targeting strategies involving nanotechnology to enhance PDT efficacy for cancers.
Export Options
About this article
Cite this article as:
Li Wen-Tyng, Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers, Current Drug Metabolism 2009; 10 (8) . https://dx.doi.org/10.2174/138920009790274559
DOI https://dx.doi.org/10.2174/138920009790274559 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
Call for Papers in Thematic Issues
Impact of brain tissue binding and plasma protein binding of drugs in DMPK
The impression of brain tissue binding (BTB) or plasma protein binding (PPB) in Drug Metabolism and Pharmacokinetics is critical to understanding the distribution, efficacy, and potential toxicity of drugs that target the central nervous system (CNS). BTB and high PPB influence the distribution of drugs in the body and their ...read more
Interaction between drugs and endocrine diseases
The introduction of highly active antiretroviral therapy accelerated studies and our understanding on the interaction between pharmacological therapies and endocrine diseases. Drugs can precipitate endocrine via different mechanisms, including direct alteration of hormone production and secretion, dysregulation of hormonal axis, effects on hormonal transport, receptor-binding, and cellular signalling. Common drug-induced ...read more
Metabolism-Mediated Xenobiotic Toxicity
Considering the potent modulation of biotransformation enzyme expression and activities by various therapeutic drugs and environmental chemicals, and the commonly combined exposure of humans to both drugs and the ever increasing environmental pollutants simultaneously, knowledge about the combined toxic effects by modulating biotransformation enzymes, such as P450s, UDP- glucuronosyltransferases, and ...read more
Safety evaluation of vaccine combination
Vaccine combination safety evaluation is a critical field within immunology and public health that focuses on assessing the safety and efficacy of combining different vaccines to maximize protection against various diseases while minimizing potential adverse effects. This process is significant because it ensures that vaccines can be administered together without ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Dynamic Expression of MicroRNAs (183, 135a, 125b, 128, 30c and 27a) in the Rat Pilocarpine Model and Temporal Lobe Epilepsy Patients
CNS & Neurological Disorders - Drug Targets Recent Advances in Oncological Submissions of Dendrimer
Current Pharmaceutical Design <i>In Vitro</i> Characteristics of Glioma Cells Targeting by OX26-modified Liposomal Cisplatin
Letters in Drug Design & Discovery Inhibition of Mutated Isocitrate Dehydrogenase 1 in Cancer
Medicinal Chemistry Predictive Efficacy Biomarkers of Programmed Cell Death 1/Programmed Cell Death 1 Ligand Blockade Therapy
Recent Patents on Anti-Cancer Drug Discovery Mitochondrial Superoxide Dismutase - Signals of Distinction
Anti-Cancer Agents in Medicinal Chemistry Retinal Ganglion Cell Gene Therapy and Visual System Repair
Current Gene Therapy Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
Current Pharmaceutical Design Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems
Current Medicinal Chemistry Post-Translational Modifications of PTEN and their Potential Therapeutic Implications
Current Cancer Drug Targets Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Dendrimers in Therapy for Breast and Colorectal Cancer
Current Medicinal Chemistry The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) in Cancers: Current Progress and Future Perspectives
Current Medicinal Chemistry The Emerging Role of Metabotropic Glutamate Receptors in the Pathophysiology of Chronic Stress-Related Disorders
Current Neuropharmacology Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine Imaging Tumor Metastases with Molecular Probes
Current Pharmaceutical Design Role of Cannabinoids and Endocannabinoids in Cerebral Ischemia
Current Pharmaceutical Design Role of Chemokines and Their Receptors in Cancer
Current Pharmaceutical Design